PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF

Detalles Bibliográficos
Autores principales: Kuykendall, Andrew, Bradley, Terrence, Komrokji, Rami S., Berry, Tymara, Dougherty, Souria, Sherman, Laurie, Peng, Lixian, Huang, Fei, Wan, Ying, Rodolf, Vivian, Ho, Judy, Navada, Shyamala, Mascarenhas, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429669/
http://dx.doi.org/10.1097/01.HS9.0000975628.90605.7e

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429669/
http://dx.doi.org/10.1097/01.HS9.0000975628.90605.7e

Ejemplares similares